Effect of N_ acetyl cyctein on hemodialysis patients

Effect of N-Acetyl cystein on residual renal function in chronic hemodialysis patients treated with low flux synthetic dialysis membrane

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015122325675N1

Enrollment

106

Registered

2016-01-30

Start date

2016-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hemodialysis patients. N17_N19

Interventions

Intervention 1: N_ acetyl cystein 600 mg ,from Osve company,oral twice daily for 4 weeks. Intervention 2: Placebo compatible with available standard drug oral twice daily for 4 weeks.

Treatment - Drugs

Placebo

N_ acetyl cystein 600 mg ,from Osve company,oral twice daily for 4 weeks

Placebo compatible with available standard drug oral twice daily for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients were treated with hemodialysis for at least 1 year, having more than 100 ml urine in 24 hr, treated with hemodialysis 3-times a week. Exclusion criteria: patients were currently treated with diuretics or antioxidants such as NAC, vitamin C and vitamin E.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Residual renal function. Timepoint: before intervention and one month after intervention. Method of measurement: midweek inter dialytic urine collection for measurement of urine output and calculation of residual renal kt/v and GFR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFahime Abaforush

Ahvaz University of Medical Sciences

Ajums@ac.ir+98 61 33161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026